Everand Logo

Welcome to Everand!

  • STAT

    Opinion: China isn’t yet ready to conduct clinical trials for the pharma industry

    by Anne Poli Aug 03, 2018 3 minutes
    Nearly all clinical research sites in China are hospitals. Because of that, clinical trial participants are treated exactly the same way as regular patients.

    China, with its huge population and its position as the second-largest pharmaceutical market in the world, should be poised to become a world leader in clinical trials for new drugs and devices. But it isn’t quite ready for that.

    Problems with protecting clinical trial participants, inadequate clinical trial infrastructure, and poor transparency make China an unreliable country in which to conduct a clinical trial. As a clinical research professional with more than a decade of global industry experience, I’ve seen

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
    Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
    STAT1 min read
    USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
    With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
    Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

    Related Books & Audiobooks